Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
92.08
+1.77 (1.96%)
Mar 20, 2026, 10:51 AM EDT - Market open
Rhythm Pharmaceuticals Revenue
In the year 2025, Rhythm Pharmaceuticals had annual revenue of $189.76M with 45.83% growth. Rhythm Pharmaceuticals had revenue of $57.25M in the quarter ending December 31, 2025, with 36.87% growth.
Revenue (ttm)
$189.76M
Revenue Growth
+45.83%
P/S Ratio
32.50
Revenue / Employee
$458,350
Employees
414
Market Cap
6.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 189.76M | 59.63M | 45.83% |
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Mirum Pharmaceuticals | 521.31M |
| Protagonist Therapeutics | 46.02M |
| Kymera Therapeutics | 39.21M |
| Arcellx | 22.29M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 4.04M |
RYTM News
- 7 hours ago - Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript - Seeking Alpha
- 16 hours ago - Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - GlobeNewsWire
- 3 days ago - Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript - Seeking Alpha
- 3 days ago - Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial - Reuters
- 3 days ago - Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial - GlobeNewsWire
- 4 days ago - Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision - Seeking Alpha
- 18 days ago - Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity - GlobeNewsWire
- 21 days ago - Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript - Seeking Alpha